Sanofi Says Vaccines Getting Back On Track, Rejects M&A
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has addressed its vaccine manufacturing issues and is about to resubmit MS therapy Lemtrada to FDA; it reported a 4.7% sales increase in the first quarter, driven by growth in its diabetes and consumer health divisions and Genzyme.
You may also be interested in...
Emerging Markets Earnings Roundup: Sanofi (Part 10)
Sanofi CEO Christopher Viehbacher gave analysts a rundown on emerging markets and the scope for the Sanofi Pasteur business along with a pipeline of biologic products that has led the company to ramp up marketing and data gathering.
Emerging Markets Earnings Roundup: Sanofi (Part 10)
Sanofi CEO Christopher Viehbacher gave analysts a rundown on emerging markets and the scope for the Sanofi Pasteur business along with a pipeline of biologic products that has led the company to ramp up marketing and data gathering.
Preparing For Battle: PCSK9 Sponsors Stake Their Ground
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.